Bisphosphonates Labels Should Discuss Duration Of Use, Advisory Panels Conclude

But members of FDA's Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees acknowledged the lack of definitive evidence on potential risks from long-term use of the osteoporosis drugs.